comparemela.com

Latest Breaking News On - Avecho biotechnology - Page 4 : comparemela.com

ASX Health Stocks: Cannabis biotech Avecho begins dosing patients in CBD gel study to treat osteoarthritis

PEAK ASSET: AFTERNOON WRAP 10 FEBRUARY: | ASX gains 0 5% as info tech surges | China blue-chips scale over 13-year high on recovery cheer; Hong Kong up | Avecho Biotechnology raises $5 06m to develop pharmaceutical cannabinoid products |

Price Change: $0.013 +8.33% If you would like more information on future Peak deals, please don’t hesitate to get in touch. Follow Peak Asset The trustee for Peak Asset Management Unit Trust (“Peak”) is a corporate authorised representative (#1249050) of Equity Underwriters Pty Ltd (AFSL #244040). Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs.  Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances.  If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this info

PEAK ASSET: AFTERNOON WRAP 08 FEBRUARY: | ASX reaches new 11-month high | China, Hong Kong stocks rise as virus worries ease | Golden Deeps returns to Professor and Waldman cobalt-silver projects amid cobalt rebound |

Price Change: $0.012 Unchanged If you would like more information on future Peak deals, please don’t hesitate to get in touch. Follow Peak Asset The trustee for Peak Asset Management Unit Trust (“Peak”) is a corporate authorised representative (#1249050) of Equity Underwriters Pty Ltd (AFSL #244040). Peak accepts no responsibility for any views expressed and marketing material contained in this email except where the message specifically states otherwise and the sender is authorised to state them to be the views of Peak. Information provided in this email is general advise only and does take account your objectives, financial situation or needs.  Before acting on any advice in this email, Peak recommends that you consider whether it is appropriate for your circumstances.  If this email contains reference to any financial products, you should obtain the current Product Disclosure Statement (PDS) or other disclosure documents for the particular products and consider this in

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.